Rosuvastatin reduces neointima formation in a rat model of balloon injury

European Journal of Medical Research

Volumn 15, Issue 11, 2010, Pages 461-467

  Preusch, Michael R ^a,b   Vanakaris, A ^a   Bea, F ^a   Ieronimakis, N ^b   Shimizu, T ^b   Konstandin, M ^a   Morris Rosenfeld, S ^a   Albrecht, C ^a   Kranzhofer A ^c   Katus, H A ^a   Blessing, E ^a   Kranzhofer R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; ROSUVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; IN VIVO STUDY; INTIMA; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; STAINING;

EID: 78650182761     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-15-11-461     Document Type: Article

References (47)

1. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol. 2000;81:63-88 (Pubitemid 30253349)
2. Andres V. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis. Int J Mol Med. 1998;2:81-89
3. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouché A, van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997;150:761-776 (Pubitemid 27073802)
4. Takamiya M, Okigaki M, Jin D, Takai S, Nozawa Y, Adachi Y, Urao N, Tateishi K, Nomura T, Zen K, Ashihara E, Miyazaki M, Tatsumi T, Takahashi T, Matsubara H. Granulocyte colony-stimulating factor-mobilized circulating c-Kit+/Flk-1+ progenitor cells regenerate endothelium and inhibit neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2006;26: 751-7
5. Smith JD, Bryant SR, Couper LL, Vary CP, Gotwals PJ, Koteliansky VE, Lindner V. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimai lesion formation but not endothelial growth. Circ Res. 1999;84:1212-1222
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50
7. Cheng XW, Kuzuya M, Sasaki T, Kanda S, Tamaya-Mori N, Koike T, Maeda K, Nishitani E, Igutchi A. Green tea catechins inhibit neointimal hyperplasia in a rat carotid arterial injury model by TIMP-2 overexpression. Cardiovasc Res. 2004;62:594-602 (Pubitemid 38648974)
8. Bendeck MP, Zempo M, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in rat. Circ Res. 1994;75:539-45
9. Pinney SP, Chen HJ, Liang D, Wang X, Schwartz A, Rabbani LE. Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. J Cardiovasc Pharmacol. 2003;42:469-76
10. Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, Caplan SL, Jeng AY. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann N Y Acad Sci. 1999;878:179-90
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207
13. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriographie. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89: 959-68
14. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R. HMG-CoA reductase inhibitors. In vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb Vasc Res. 1993;13:571-8
15. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9 (Pubitemid 34219772)
16. van der Harst P, Groenewegen HC, Roks AJ, Buikema H, Zijlstra F, van Gilst WH, de Smet BJ. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron Artery Dis. 2008;19: 47-53 (Pubitemid 351339967)
17. Kappert K, Leppänen O, Paulsson J, Furuhashi M, Carlsson MA, Heldin CH, Fätkenheuer G, Rosenkranz S, Ostman A. Highly active antiretroviral therapy attenuates reendothelialization and alters neointima formation in the rat carotid artery after balloon injury. J Acquir Immune Defic Syndr. 2006;43:383-92
18. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001; 87: 28-32
19. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005;19:804-6
20. Evans J, Powell JT, Schwalbe E, Loftus IM, Thompson MM. Simvastatin attenuates the activity of matrix metalloproteinase-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007;100:23-7
21. Werner N, Priller J, Lauf U, Endres M, Böhm M, Dirnagl U, Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22:1567-72
22. Lyons JG, Birkedal-Hansen B, Moore WGI, O'Grady RLO, Birkedal-Hansen H. Characteristics of a 95-kD matrix-metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991;30:1449-1456
23. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, Kim JJ, Mintz GS, Park SW. (2005) Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 45:351-356
24. Maisel WH. Unanswered questions - drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356: 981-4
25. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998;98:1802-20
26. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3 and -9 from vascular smooth muscle cells in macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769-75 (Pubitemid 36566165)
27. Clowes AW, Reidy MA, Clowes MM. Kinetics of Cellular Proliferation after Arterial Injury I. Smooth Muscle Growth in the Absence of Endothelium. Lab Invest 1983;49:327-33
28. Indolfi C, Torella D, Coppola C, Stabile E, Esposito G, Curcio A, Pisani A, Cavuto L, Arcucci O, Cireddu M, Troncone G, Chiariello M. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. Am J Physiol Heart Circ Physiol. 2002;283:760-7
29. Kiyan J, Kusch A, Tkachuk S, Krämer J, Haller H, Dietz R, Smith G, Dumler I. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis. 2007;195:254-61 (Pubitemid 350087953)
30. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis. 2003;167:187-94 (Pubitemid 36773519)
31. Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;23:58-63
32. Han CI, Campbell GR, Campbell JH. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 2001;38:113-119 (Pubitemid 32337213)
33. Bauters C, Isner JM. The biology of restenosis. Prog Cardiovasc Dis. 1997;40:107-116
34. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405 (Pubitemid 32730786)
35. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208-15.
36. Haudenschild CC, Schwartz SM. Endothelial regeneration. II. Restitution of endothelial continuity. Lab Invest. 1979;41:407-18.
37. Schäfer K, Kaiser K, Konstandinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost. 2005;93:145-52 (Pubitemid 40124269)
38. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-61
39. Ramcharan AS, Van Stralen KJ, Snoep JD, MantelTeeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost. 2009;7:514-20
40. Tutar E, Ozcan M, Kilickap M, Gülec S, Aras O, Pamir G, Oral D, Dandelet L, Key NS. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation. 2003;108:1581-4
41. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002;105:3017-24
42. Lee CH, de Feyter P, Serruys PW, Saia F, Lemos PA, Goedhart D, Soares PR, Umans VA, Ciccone M, Cortellaro M. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart 2004;90:1156-61
43. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ. Effect of maximal doses of atorvastatin versus Rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol 2008;101:315-318 (Pubitemid 351175627)
44. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001;104:576-581
45. Endo A, Tsujita Y, Kuroda M, Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochem Biophys Acta. 1979;575:266-276 (Pubitemid 10196661)
46. Wang YX, Martin-McNulty B, Huw LY, da Cunha V, Post J, Hinchman J, Vergona R, Sullivan ME, Dole W, Kauser K. Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 2002;162: 23-31
47. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest. 1980;66:1094-100 (Pubitemid 11233811)